VIR
Vir Biotechnology, Inc.Company Information
- Company Name
- Vir Biotechnology, Inc.
- CIK
- CIK0001706431
- Category
- Large accelerated filer
- Ticker: Exchange
- VIR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- VIR
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-06-01
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,849,570
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 146,806,298
- Shares outstanding
- 167,719,015
- Ownership
- 87.53%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 18.88%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 279 | 274 | 232 | 170 | 211 | 274 | 223 | 168 | 297 | 161 | 242 | 452 | ||||||
| Marketable Securities Current | 250 | 196 | 229 | 328 | 388 | 517 | 678 | 741 | 850 | 985 | 1,271 | 1,234 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | 2 | 2 | 2 | 2 | 88 | 88 | 89 | 90 | 14 | 13 | 13 | 13 | ||||||
| Equity Securities Fv Ni | 4 | 6 | 6 | 9 | 7 | 11 | 4 | 6 | 4 | - | 10 | - | ||||||
| Prepaid Expense And Other Assets Current | 39 | 45 | 45 | 37 | 41 | 42 | 48 | 43 | 41 | 50 | 53 | 59 | ||||||
| Assets Current | 574 | 523 | 514 | 546 | 736 | 932 | 1,042 | 1,047 | 1,206 | 1,213 | 1,588 | 1,769 | ||||||
| Intangible Assets Net Excluding Goodwill | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 19 | 19 | 22 | 23 | 25 | ||||||
| Goodwill | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | ||||||
| Property Plant And Equipment Net | 50 | 53 | 56 | 58 | 61 | 62 | 63 | 65 | 66 | 92 | 96 | 99 | ||||||
| Operating Lease Right Of Use Asset | 59 | 61 | 62 | 64 | 65 | 59 | 60 | 61 | 62 | 70 | 71 | 73 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | ||||||
| Long Term Investments | 475 | 333 | 315 | 304 | 286 | 218 | 190 | 271 | 280 | 360 | 105 | 40 | ||||||
| Other Assets | 25 | 24 | 25 | 16 | 13 | 6 | 12 | 12 | 13 | 12 | 12 | 15 | ||||||
| Assets | 1,215 | 1,026 | 1,003 | 1,019 | 1,193 | 1,308 | 1,399 | 1,498 | 1,670 | 1,794 | 1,919 | 2,045 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 18 | 5 | 10 | 7 | 12 | 4 | 5 | 7 | 4 | 7 | 6 | 4 | ||||||
| Accrued Liabilities And Other Liabilities | 77 | 68 | 83 | 68 | 83 | 104 | 99 | 95 | 75 | 72 | 104 | 146 | ||||||
| Deferred Revenue Current | - | - | - | 0 | 10 | 12 | 13 | 15 | 17 | 15 | 65 | 15 | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | 0 | 0 | 0 | 18 | 16 | - | - | - | 0 | - | ||||||
| Liabilities Current | 95 | 74 | 93 | 75 | 105 | 137 | 120 | 117 | 96 | 94 | 175 | 165 | ||||||
| Deferred Revenue Noncurrent | - | - | - | - | - | - | - | - | - | 2 | 2 | 53 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | 9 | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 84 | 87 | 89 | 91 | 93 | 88 | 90 | 93 | 95 | 109 | 112 | 114 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 34 | 33 | 34 | 34 | 34 | 24 | 24 | 33 | 31 | 28 | 26 | 24 | ||||||
| Other Liabilities Noncurrent | 19 | 19 | 22 | 13 | 13 | 15 | 15 | 14 | 14 | 14 | 16 | 13 | ||||||
| Liabilities | 232 | 213 | 238 | 223 | 245 | 264 | 248 | 258 | 236 | 247 | 329 | 370 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 2,230 | 2,140 | 1,965 | 1,953 | 1,941 | 1,927 | 1,912 | 1,895 | 1,878 | 1,853 | 1,829 | 1,799 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -5 | -3 | -2 | -2 | -2 | -2 | -2 | 1 | -3 | -2 | -1 | -2 | ||||||
| Retained Earnings Accumulated Deficit | -1,243 | -1,323 | -1,198 | -1,155 | -992 | -881 | -760 | -655 | -441 | -303 | -238 | -122 | ||||||
| Stockholders Equity | 982 | 813 | 765 | 796 | 947 | 1,044 | 1,150 | 1,241 | 1,434 | 1,547 | 1,590 | 1,675 | ||||||
| Liabilities And Stockholders Equity | 1,215 | 1,026 | 1,003 | 1,019 | 1,193 | 1,308 | 1,399 | 1,498 | 1,670 | 1,794 | 1,919 | 2,045 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 169 | 161 | 139 | 139 | 139 | 138 | 137 | 137 | 137 | 136 | 135 | 134 | ||||||
| Shares Outstanding | 169 | 161 | 139 | 139 | 139 | 138 | 137 | 137 | 137 | 136 | 135 | 134 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVir Biotechnology, Inc. (VIR) — SEC Financial Statements & Analysis
Vir Biotechnology, Inc. (VIR) is a biological products, (no diagnostic substances) company, incorporated in DE. Vir Biotechnology, Inc. trades on Nasdaq as: VIR. Vir Biotechnology, Inc. (VIR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Vir Biotechnology, Inc. carries a market cap of $1.71B, a P/E ratio of -6.79x, a P/B ratio of 1.74x, a P/S ratio of 5.64x, an enterprise value of $1.42B, and an EV/EBITDA multiple of -5.29x. On profitability, it posts a gross margin of 98.86%, an operating margin of -92.40%, a net margin of -83.00%, a Return on Equity (ROE) of -26.08%, a Return on Assets (ROA) of -20.91%, and a Return on Invested Capital (ROIC) of -41.74%. Per share, it reports EPS of $-1.50, diluted EPS of $-1.49, free cash flow per share of $-1.21, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 1495.93% year-over-year, net income growth of -54.26% year-over-year, and EPS growth of -62.24% year-over-year. On the balance sheet, it maintains a current ratio of 6.04x, a quick ratio of 5.63x, working capital of $478.78M, a debt-to-equity ratio of 0.24x, a debt ratio of 0.19, free cash flow of $-203.59M (TTM), and net debt of $-287.60M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.71B
- P/E TTM
- -6.79x
- EPS TTM
- $-1.50
- P/B TTM
- 1.74x
- ROE TTM
- -26.08%
- ROA TTM
- -20.91%
- Debt To Equity
- 0.24x
- Free Cash Flow TTM
- $-203.59M
- Net Revenue TTM Growth 1Y
- 1495.93%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Vir Biotechnology, Inc. in?
Vir Biotechnology, Inc. (VIR) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does VIR trade on?
Vir Biotechnology, Inc. (VIR) trades on the Nasdaq.
Where is Vir Biotechnology, Inc. incorporated?
Vir Biotechnology, Inc. is incorporated in DE.
When was Vir Biotechnology, Inc. (VIR)'s most recent SEC filing?
Vir Biotechnology, Inc. (VIR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is VIR's market cap?
Vir Biotechnology, Inc. (VIR) has a market capitalization of $1.71B as of 2026-06-30.
What is VIR's EPS (earnings per share)?
Vir Biotechnology, Inc. (VIR)'s trailing twelve month EPS is $-1.50 as of 2026-06-30.
What is VIR's ROE (return on equity)?
Vir Biotechnology, Inc. (VIR)'s trailing twelve month Return on Equity (ROE) is -26.08% as of 2026-06-30.
What is VIR's ROA (return on assets)?
Vir Biotechnology, Inc. (VIR)'s trailing twelve month Return on Assets (ROA) is -20.91% as of 2026-06-30.
What is VIR's ROIC (return on invested capital)?
Vir Biotechnology, Inc. (VIR)'s trailing twelve month Return on Invested Capital (ROIC) is -41.74% as of 2026-06-30.
What is VIR's EV/EBITDA?
Vir Biotechnology, Inc. (VIR)'s trailing twelve month EV/EBITDA is -5.29x as of 2026-06-30.